279 related articles for article (PubMed ID: 18684216)
1. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants.
Vercellino M; Romagnolo A; Mattioda A; Masera S; Piacentino C; Merola A; Chiò A; Mutani R; Cavalla P
Acta Neurol Scand; 2009 Feb; 119(2):126-30. PubMed ID: 18684216
[TBL] [Abstract][Full Text] [Related]
2. Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study.
Leone MA; Bonissoni S; Collimedaglia L; Tesser F; Calzoni S; Stecco A; Naldi P; Monaco F
Mult Scler; 2008 May; 14(4):485-93. PubMed ID: 18208889
[TBL] [Abstract][Full Text] [Related]
3. Multiple sclerosis: relapses and timing of remissions.
Iuliano G; Napoletano R; Esposito A
Eur Neurol; 2008; 59(1-2):44-8. PubMed ID: 17917457
[TBL] [Abstract][Full Text] [Related]
4. Predictors of relapse rate in MS clinical trials.
Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
[TBL] [Abstract][Full Text] [Related]
5. The incomplete nature of multiple sclerosis relapse resolution.
Lublin FD
J Neurol Sci; 2007 May; 256 Suppl 1():S14-8. PubMed ID: 17337274
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors of multiple sclerosis in Lebanon.
Yamout B; Itani S; Arabi A; Hamzeh D; Yaghi S
Int J Neurosci; 2010 Mar; 120(3):206-10. PubMed ID: 20374088
[TBL] [Abstract][Full Text] [Related]
7. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.
Young PJ; Lederer C; Eder K; Daumer M; Neiss A; Polman C; Kappos L;
Neurology; 2006 Sep; 67(5):804-8. PubMed ID: 16966541
[TBL] [Abstract][Full Text] [Related]
8. A composite score to predict short-term disease activity in patients with relapsing-remitting MS.
Sormani MP; Rovaris M; Comi G; Filippi M
Neurology; 2007 Sep; 69(12):1230-5. PubMed ID: 17875911
[TBL] [Abstract][Full Text] [Related]
9. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation.
Fagius J; Lundgren J; Oberg G
Mult Scler; 2009 Feb; 15(2):229-37. PubMed ID: 18805841
[TBL] [Abstract][Full Text] [Related]
10. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B
Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027
[TBL] [Abstract][Full Text] [Related]
11. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis.
O'Rourke K; Walsh C; Antonelli G; Hutchinson M
Mult Scler; 2007 Apr; 13(3):336-42. PubMed ID: 17439902
[TBL] [Abstract][Full Text] [Related]
12. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
13. Temporal evolution of remission following multiple sclerosis relapse and predictors of outcome.
Hirst CL; Ingram G; Pickersgill TP; Robertson NP
Mult Scler; 2012 Aug; 18(8):1152-8. PubMed ID: 22217582
[TBL] [Abstract][Full Text] [Related]
14. Are initial demyelinating event recovery and time to second event under differential control?
West T; Wyatt M; High A; Bostrom A; Waubant E
Neurology; 2006 Sep; 67(5):809-13. PubMed ID: 16966542
[TBL] [Abstract][Full Text] [Related]
15. Neurofilament light as a prognostic marker in multiple sclerosis.
Salzer J; Svenningsson A; Sundström P
Mult Scler; 2010 Mar; 16(3):287-92. PubMed ID: 20086018
[TBL] [Abstract][Full Text] [Related]
16. Gender as a prognostic factor and its impact on the incidence of multiple sclerosis in Lorraine, France.
Debouverie M
J Neurol Sci; 2009 Nov; 286(1-2):14-7. PubMed ID: 19691994
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P
Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.
Glad SB; Nyland HI; Aarseth JH; Riise T; Myhr KM
Mult Scler; 2009 Aug; 15(8):942-50. PubMed ID: 19570821
[TBL] [Abstract][Full Text] [Related]
19. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
[TBL] [Abstract][Full Text] [Related]
20. Temporal relationship between environmental influenza A and Epstein-Barr viral infections and high multiple sclerosis relapse occurrence.
Oikonen M; Laaksonen M; Aalto V; Ilonen J; Salonen R; Erälinna JP; Panelius M; Salmi A
Mult Scler; 2011 Jun; 17(6):672-80. PubMed ID: 21212088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
